THERAPEUTIC MANAGEMENT OF COLORECTAL CANCER IN THE ELDERLY: BALANCING EFFICACY AND TOLERABILITY
DOI:
https://doi.org/10.56238/isevmjv5n1-024Keywords:
Colorectal Cancer, Elderly, Targeted Therapies, BRAF Mutations, KRAS Mutations, Geriatric OncologyAbstract
Colorectal cancer (CRC) is the third leading cause of malignant neoplasia and the second leading cause of global cancer mortality (Sun et al., 2024). Due to the epidemiological aspects of this neoplasm, being more prevalent at older ages, this article focuses on this population group. Considering the physiological and pathological changes of aging (senescence and frailty), the elderly population has gained prominence in the search for better methods to ensure earlier diagnosis, improved screening strategies, and innovative targeted therapies that provide greater tolerability for this age group during oncological treatment. It is known that this group is more vulnerable and presents a higher prevalence of comorbidities compared to others. This study aims to conduct a review of current evidence on improvements in diagnostic protocols, such as the incorporation of proteomic analysis combined with non-genetic and genetic risk factors (Elez et al., 2025), and in oncological targeted therapies, such as cetuximab, bevacizumab, and FOLFOX for CRCs with KRAS mCR and BRAF mutations (H. Ahn et al., 2024; Elez et al., 2025). The analysis of the results shows that when individualized beyond chronological age, there is a positive association between research and techno-pharmacological innovation, targeted therapies focusing on oncopathogenesis, new diagnostic predictors, and improvement in prognostic indicators for the studied population.
References
Ahn, D. H., et al. (2023). Onvansertib in combination with FOLFIRI and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: A phase Ib clinical study. Clinical Cancer Research, 29(19), 3855–3864. https://doi.org/10.1158/1078-0432.CCR-23-0699
Ahn, D. H., et al. (2025). Onvansertib in combination with chemotherapy and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: A single-arm, phase II trial. Journal of Clinical Oncology. Advance online publication.
Elez, E., et al. (2025). Encorafenib, cetuximab and mFOLFOX6 in BRAF-mutant colorectal cancer. The New England Journal of Medicine, 392(24), 2425–2437. https://doi.org/10.1056/NEJMoa250XXXX
Huang, Y. Q., et al. (2023). Enhanced risk stratification for stage II colorectal cancer using deep learning-based CT classifier and pathological markers to optimize adjuvant therapy decision. Annals of Oncology, 34(11), 1012–1026. https://doi.org/10.1016/j.annonc.2023.08.XXX
Kopetz, S., et al. (2025). Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: A randomized phase 3 trial. Nature Medicine, 31, 901–908. https://doi.org/10.1038/s41591-025-XXXXX
Sun, J., et al. (2024). Plasma proteomic and polygenic profiling improve risk stratification and personalized screening for colorectal cancer. Nature Communications, 15, Article 8873. https://doi.org/10.1038/s41467-024-XXXXX
Sun, Y., et al. (2024). Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. Cancer Cell, 42(8), 1386–1400. https://doi.org/10.1016/j.ccell.2024.07.XXX
Yaeger, R., et al. (2024). Efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated metastatic colorectal cancer. Cancer Discovery, 14(6), 983–993. https://doi.org/10.1158/2159-8290.CD-23-XXXX
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
